Hoffmann-la Roche Inc.

Pierre Charles Wyss

Patrizio Mattei

Luca Claudio Gobbi

Robert Narquizian

Thomas Luebbers

Emilio Kyburz

Mose Da Prada

Renato Joos

The present invention provides compounds of formula (I):wherein R, R, R, R, Rand Rare as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

Pyrido[2,1-a]isoquinoline derivatives

Pyrido&lsqb;2,1-A&rsqb;Isoquinoline derivatives

Benzamides of the formula ##STR1## wherein R.sup.1 and R.sup.2 each independently is hydrogen, halogen, lower alkyl, lower alkoxy, cyano, trifluoromethyl, sulfamoyl, mono(lower alkyl)sulfamoyl or di(lower alkyl)sulfamoyl or R.sup.1 and R.sup.2 on adjacent carbon atoms together are a methylenedioxy group, with the proviso that R.sup.2 is different from hydrogen when R.sup.1 are bromine in the 3-position, and their pharmaceutically acceptable acid addition salts have monoamine oxidase inhibiting properties with low toxicity and can accordingly be used for the treatment of depressive states and Parkinsonism.

Benzamide derivatives

Growing community of inventors

Therwil, Switzerland

Pierre Charles Wyss